Literature DB >> 11016662

Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis.

A Nakashio1, N Fujita, S Rokudai, S Sato, T Tsuruo.   

Abstract

The serine/threonine kinase Akt (also known as protein kinase B) is a downstream effector of phosphatidylinositol-3'-kinase [PI(3)K] that is recognized as the major mediator of survival signals that protect cells from undergoing apoptosis. In the course of examining the target molecules of the topoisomerase I inhibitor topotecan, we found that topotecan treatment promoted Akt dephosphorylation that led to the inactivation of Akt in human lung cancer A549 cells. Transfection of the constitutively active akt cDNA into A549 cells resulted in the reduction of the cytotoxic effect of topotecan, indicating that inhibition of the Akt pathway played an important role in exhibition of topotecan-mediated cytotoxic effects. Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016662

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis.

Authors:  Susumu Rokudai; Naoya Fujita; Osamu Kitahara; Yusuke Nakamura; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition.

Authors:  Kazuhiro Katayama; Naoya Fujita; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

4.  Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

Authors:  Sherry X Yang; Joseph P Costantino; Chungyeul Kim; Eleftherios P Mamounas; Dat Nguyen; Jong-Hyeon Jeong; Norman Wolmark; Kelley Kidwell; Soonmyung Paik; Sandra M Swain
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

5.  CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.

Authors:  Sara Bar-Yehuda; Lea Madi; Daniel Silberman; Slosman Gery; Maya Shkapenuk; Pnina Fishman
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

6.  A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells.

Authors:  Priyajit Chatterjee; Soma Seal; Sandip Mukherjee; Rakesh Kundu; Mantu Bhuyan; Nabin C Barua; Pranab K Baruah; Santi Prasad Sinha Babu; Samir Bhattacharya
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

7.  Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.

Authors:  Sebastian Kuger; Dorothea Graus; Rico Brendtke; Nadine Günther; Astrid Katzer; Paul Lutyj; Bülent Polat; Manik Chatterjee; Vladimir L Sukhorukov; Michael Flentje; Cholpon S Djuzenova
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

8.  PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.

Authors:  Uri Elia; Eliezer Flescher
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.

Authors:  Fu-Yue Zeng; Jimmy Cui; Lingling Liu; Taosheng Chen
Journal:  Cancer Lett       Date:  2009-05-12       Impact factor: 8.679

Review 10.  New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Authors:  Sherry X Yang; Eric Polley; Stanley Lipkowitz
Journal:  Cancer Treat Rev       Date:  2016-03-09       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.